Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016
Published Oct 19, 2016
197 pages — Published Oct 19, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H2 2016, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9, 15, 19 and 7 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Chronic Kidney Disease (Chronic Renal Failure).

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Geni

  
Source:
Document ID
GMDHC8538IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Chronic Kidney Disease (Chronic Renal Failure) Overview121
Therapeutics Development132
  Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Overview131
  Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) Comparative Analysis141
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies153
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes181
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Products Glance193
  Late Stage Products191
  Clinical Stage Products201
  Early Stage Products211
Chronic Kidney Disease (Chronic Renal Failure) Products under Development by Companies223
Chronic Kidney Disease (Chronic Renal Failure) Products under Investigation by Universities/Institutes251
Chronic Kidney Disease (Chronic Renal Failure) Companies Involved in Therapeutics Development2636
  Acceleron Pharma, Inc.261
  Angion Biomedica Corp.271
  Astellas Pharma Inc.281
  AstraZeneca Plc291
  Bayer AG301
  Bio-inRen311
  BioAegis Therapeutics, Inc.321
  Boehringer Ingelheim GmbH331
  Bristol-Myers Squibb Company341
  Cellmid Limited351
  Complexa, Inc.361
  CTI BioPharma Corp.371
  Evotec AG381
  F. Hoffmann-La Roche Ltd.391
  Gilead Sciences, Inc.401
  GNI Group Ltd.411
  Intercept Pharmaceuticals, Inc.421
  Lupin Limited431
  Navya Biologicals Pvt Ltd441
  Nippon Zoki Pharmaceutical Co., Ltd.451
  Novartis AG461
  Otsuka Holdings Co., Ltd.471
  Prismic Pharmaceuticals, Inc.481
  Prolong Pharmaceuticals, LLC491
  ProMetic Life Sciences Inc.501
  Reata Pharmaceuticals, Inc.511
  Red Glead Discovery AB521
  RegenMedTX, LLC531
  Resverlogix Corp.541
  Sphaera Pharma Pvt. Ltd.551
  Stelic Institute &Co., Inc.561
  Taisho Pharmaceutical Co., Ltd.571
  Thrasos Therapeutics Inc.581
  Toray Industries, Inc.591
  VBS Pharmaceuticals601
  Vicore Pharma AB611
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Assessment6214
  Assessment by Monotherapy Products621
  Assessment by Combination Products631
  Assessment by Target644
  Assessment by Mechanism of Action684
  Assessment by Route of Administration722
  Assessment by Molecule Type742
Drug Profiles76106
  (palmidrol + silibinin) Drug Profile761
  ambrisentan Drug Profile772
  ANG-3070 Drug Profile791
  ANG-3281 Drug Profile801
  ANG-3586 Drug Profile811
  apabetalone Drug Profile829
  AS-2444697 Drug Profile911
  bardoxolone methyl Drug Profile925
  BI-655088 Drug Profile971
  BLR-400 Drug Profile981
  BMS-986177 Drug Profile991
  BRN-1889 Drug Profile1001
  C-21 Drug Profile1012
  CAB-101 Drug Profile1031
  calcium succinate Drug Profile1041
  CAR Peptide Drug Profile1051
  cardiotoxin Drug Profile1061
  Cell Therapy for Chronic Kidney Disease and Metabolic Disorders Drug Profile1071
  CXA-10 Drug Profile1082
  dapagliflozin propanediol Drug Profile1107
  Drug for Kidney Diseases Drug Profile1171
  F-351 Drug Profile1182
  finerenone Drug Profile1202
  INT-767 Drug Profile1221
  KBP-5074 Drug Profile1231
  LHW-090 Drug Profile1241
  NAV-003 Drug Profile1251
  NZ-419 Drug Profile1261
  obinutuzumab Drug Profile1277
  pacritinib Drug Profile13411
  PBI-4050 Drug Profile1455
  PBI-4419 Drug Profile1501
  Recombinant Plasma Gelsolin Replacement for Renal Disease Drug Profile1511
  Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis Drug Profile1522
  Sanguinate Drug Profile1542
  Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism Drug Profile1561
  Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for Chronic Kidney Disease and Hypertension Drug Profile1571
  Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease Drug Profile1581
  Small Molecules for Chronic Kidney Disease Drug Profile1591
  Small Molecules for Chronic Kidney Disease Drug Profile1601
  Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology Drug Profile1611
  sotatercept Drug Profile1625
  SP-20103 Drug Profile1671
  SPR-494 Drug Profile1681
  STNM-310 Drug Profile1691
  Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease Drug Profile1701
  Synthetic Peptides for Chronic Kidney Disease Drug Profile1711
  TNT-009 Drug Profile1722
  tolvaptan Drug Profile1744
  torsemide ER Drug Profile1781
  TRC-101 Drug Profile1791
  TS-143 Drug Profile1801
  Vida-5 Drug Profile1811
Chronic Kidney Disease (Chronic Renal Failure) Dormant Projects1823
Chronic Kidney Disease (Chronic Renal Failure) Discontinued Products1851
Chronic Kidney Disease (Chronic Renal Failure) Product Development Milestones18610
  Featured News &Press Releases1861
    Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure1861
    Aug 05, 2016: CDSCO requests further data for granting additional indication for Ambrisentan tablet 5mg/10mg1861
    Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial1871
    Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs1871
    May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis &Transplant Association Congress (ERA-EDTA)1881
    Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference1891
    Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"1892
    Jun 02, 2015: Combination of Agents in NEFROSIL found to be Highly Effective in Renal Disease Model1911
    Jun 01, 2015: Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis &Transplant Association Congress1911
    Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China1921
    Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 20141921
    Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease - Mineral and Bone Disorder1931
    Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402)1931
    Apr 23, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis1941
    Mar 17, 2014: Acceleron and Celgene Announce Interim Clinical Data for Sotatercept in Patients with End Stage Renal Disease on Hemodialysis at the 2014 National Kidney Foundation Spring Clinical Meeting1942
Appendix1962
  Methodology1961
  Coverage1961
  Secondary Research1961
  Primary Research1961
  Expert Panel Validation1961
  Contact Us1961
  Disclaimer1971

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016" Oct 19, 2016. Alacra Store. May 05, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Kidney-Disease-Chronic-Renal-Failure-Pipeline-Review-H2-2016-2088-16666>
  
APA:
Global Markets Direct - Market Research. (2016). Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2016 Oct 19, 2016. New York, NY: Alacra Store. Retrieved May 05, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Kidney-Disease-Chronic-Renal-Failure-Pipeline-Review-H2-2016-2088-16666>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.